- Home
- RLYB vs CNTB Comparison
RLYB vs CNTB Comparison
Compare RLYB & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLYB
- CNTB
- Stock Information
- Founded
- RLYB 2018
- CNTB 2012
- Country
- RLYB United States
- CNTB United States
- Employees
- RLYB N/A
- CNTB N/A
- Industry
- RLYB Biotechnology: Pharmaceutical Preparations
- CNTB Biotechnology: Pharmaceutical Preparations
- Sector
- RLYB Health Care
- CNTB Health Care
- Exchange
- RLYB Nasdaq
- CNTB Nasdaq
- Market Cap
- RLYB 45.2M
- CNTB 53.9M
- IPO Year
- RLYB 2021
- CNTB 2021
- Fundamental
- Price
- RLYB $0.92
- CNTB $0.98
- Analyst Decision
- RLYB Buy
- CNTB Strong Buy
- Analyst Count
- RLYB 6
- CNTB 1
- Target Price
- RLYB $8.10
- CNTB $8.00
- AVG Volume (30 Days)
- RLYB 125.7K
- CNTB 28.6K
- Earning Date
- RLYB 11-07-2024
- CNTB 09-05-2024
- Dividend Yield
- RLYB N/A
- CNTB N/A
- EPS Growth
- RLYB N/A
- CNTB N/A
- EPS
- RLYB N/A
- CNTB N/A
- Revenue
- RLYB $598,000.00
- CNTB $24,116,000.00
- Revenue This Year
- RLYB N/A
- CNTB N/A
- Revenue Next Year
- RLYB N/A
- CNTB $63.90
- P/E Ratio
- RLYB N/A
- CNTB N/A
- Revenue Growth
- RLYB N/A
- CNTB N/A
- 52 Week Low
- RLYB $0.84
- CNTB $0.90
- 52 Week High
- RLYB $3.46
- CNTB $2.66
- Technical
- Relative Strength Index (RSI)
- RLYB 39.33
- CNTB 42.93
- Support Level
- RLYB $0.84
- CNTB $1.00
- Resistance Level
- RLYB $1.24
- CNTB $1.05
- Average True Range (ATR)
- RLYB 0.08
- CNTB 0.08
- MACD
- RLYB -0.02
- CNTB -0.01
- Stochastic Oscillator
- RLYB 20.30
- CNTB 10.07
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.